WAUI
NVO

WELLINGTON-ALTUS USA INC.’s Novo Nordisk NVO Stock Holding History

WELLINGTON-ALTUS USA INC.’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.2K Buy
+2,400
New +$103K 0.06% 229
2026
Q1 		– Sell
-2,400
Closed -$122K – 737
2025
Q4 		$122K Buy
+2,400
New +$123K 0.09% 182

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

WELLINGTON-ALTUS USA INC.'s NVO Position: Q2 2026 in Review

WELLINGTON-ALTUS USA INC. opened a new position in Novo Nordisk (NVO) in Q2 2026: 2,400 shares worth $88.2K. The stake represents 0.06% of the portfolio and ranks #229 among its holdings. This is a return to the name: WELLINGTON-ALTUS USA INC. previously reported a position in NVO as recently as Q4 2025.

WELLINGTON-ALTUS USA INC. first reported a position in NVO in Q4 2025 and has held it in 2 quarters since. The position peaked at $122K in Q4 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • WELLINGTON-ALTUS USA INC. held 2,400 shares of Novo Nordisk worth $88.2K as of Q2 2026.
  • Novo Nordisk was a new WELLINGTON-ALTUS USA INC. position in Q2 2026.
  • Novo Nordisk made up 0.06% of WELLINGTON-ALTUS USA INC.'s portfolio in Q2 2026, its #229 holding.
  • WELLINGTON-ALTUS USA INC. first reported a position in Novo Nordisk in Q4 2025 and has held it in 2 quarters since.
  • WELLINGTON-ALTUS USA INC.'s Novo Nordisk position peaked at $122K in Q4 2025.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on WELLINGTON-ALTUS USA INC.'s 13F filing for Q2 2026, filed 17 Sep 2026.